Skip to main content

Table 3 Changes in outcome measures (week 0 vs. week 8, week 0 vs. week 20) after treatment completion in the four groups

From: Factors contributing to cognitive improvement effects of acupuncture in patients with mild cognitive impairment: a pilot randomized controlled trial

Groups Dependent variables Week 0 (M±SD) Week 8 (M±SD) Week 20 (M±SD) Difference (W8–W0) Z (p)a Difference (W20–W0) Z (p)a x2 (p)b
BA group (n=8) MoCA-K 19.63 ±1.51 25.75 ±1.75 25.75 ±2.82 6.13±1.81 −2.54 (0.011) 6.13±3.00 −2.53 (0.012) 12.80 (0.002)
ADAS-K-cog 12.13 ±5.59 5.75 ±2.38 4.63±3.25 −6.38±5.71 −2.32 (0.021) −7.50±5.37 −2.53 (0.012) 9.75 (0.008)
CES-D 15.63 ±5.88 10.25 ±4.03 10.63 ±5.78 −5.38 ±5.37 −2.31 (0.021) −5.00 ±7.67 −1.61 (0.108) 4.35 (0.114)
K-ADL 7.00 ±0.00 7.00 ±0.00 7.00 ±0.00 0.00±0.00 0.00 (1.000) 0.00±0.00 0.00 (1.000) 0.00 (1.000)
K-IADL 10.75±0.89 10.13 ±0.35 11.00±1.41 −0.63 ±1.06 −1.52 (0.129) 0.25±1.83 −0.34 (0.732) 3.39 (0.183)
EQ-5D-5L 6.75 ±1.28 5.88 ±1.13 5.88 ±0.64 −0.88 ±0.64 −2.33 (0.020) −0.88±1.13 −1.90 (0.058) 7.15 (0.028)
AS group (n=8) MoCA-K 20.88 ±1.36 24.38 ±3.25 25.00 ±3.38 3.50±2.98 −2.21 (0.027) 4.13±3.36 −2.21 (0.027) 10.18 (0.006)
ADAS-K-cog 7.00 ±2.83 4.50 ±1.93 3.38 ±1.77 −2.50±3.16 −1.90 (0.058) −3.63±2.83 −2.21 (0.027) 7.64 (0.022)
CES-D 15.13 ±6.42 9.50 ±6.91 13.38 ±9.38 −5.63 ±7.19 −2.00 (0.046) −1.75 ±9.10 −0.73 (0.465) 4.36 (0.113)
K-ADL 7.00 ±0.00 7.00 ±0.00 7.00 ±0.00 0.00.±0.00 0.00 (1.000) 0.00.±0.00 0.00 (1.000) 0.00 (1.00)
K-IADL 11.00 ±1.20 10.63±1.06 10.75±1.39 −0.38±0.52 −1.73 (0.083) −0.25±0.89 −0.81 (0.414) 2.36 (0.307)
EQ-5D-5L 5.75 ±0.87 5.75 ±1.17 5.50 ±1.07 0.00±0.54 0.00 (1.000) −0.25±0.71 −1.00 (0.317) 2.00 (0.368)
ND group (n=8) MoCA-K 19.38 ±2.13 21.75 ±3.11 23.13 ±3.87 2.38±2.45 −2.02 (0.043) 3.75±3.33 −2.02 (0.043) 9.58(0.008)
ADAS-K-cog 10.13 ±4.26 8.75 ±4.74 7.75 ±5.15 −1.38±3.85 −0.92 (0.357) −2.38±2.62 −1.84 (0.066) 3.44 (0.179)
CES-D 15.25 ±7.07 12.50 ±3.59 15.63 ±5.90 −2.75 ±7.15 −0.94 (0.345) 0.38±2.88 −0.27 (0.786) 2.80 (0.247)
K-ADL 7.38 ±0.74 7.25 ±0.71 7.50 ±0.93 −0.13±0.35 −1.00 (0.317) 0.13±0.35 −1.00 (0.317) 2.00 (0.368)
K-IADL 11.88±3.76 12.00 ±3.78 12.13±3.72 0.13 ±0.35 −1.00 (0.317) 0.25±0.46 −1.41 (0.157) 3.00 (0.223)
EQ-5D-5L 6.63 ±1.60 6.13±1.36 5.88 ±1.46 −0.50 ±0.76 −1.63 (0.102) −0.75±1.49 −1.30 (0.194) 2.38 (0.305)
EA group (n=8) MoCA-K 20.63 ±2.07 22.50 ±2.73 23.25 ±3.28 1.88±2.10 −2.04 (0.041) 2.63±2.62 −2.00 (0.046) 5.48 (0.061)
ADAS-K-cog 9.13 ±2.85 7.25 ±2.92 5.38 ±3.70 −1.88±2.10 −2.04 (0.041) −3.75±2.38 −2.26 (0.024) 11.00 (0.004)
CES-D 15.50 ±11.48 11.38 ±9.01 10.75 ±8.62 −4.13 ±6.40 −1.58 (0.114) −4.75 ±4.30 −2.21 (0.027) 4.33 (0.142)
K-ADL 7.00 ±0.00 7.00 ±0.00 7.00 ±0.00 0.00.±0.00 0.00 (1.000) 0.00.±0.00 0.00 (1.000) 0.00 (1.000)
K-IADL 10.25±0.46 10.13 ±0.35 10.13±0.35 −0.13±0.64 −0.58 (0.564) −0.13±0.64 −0.58 (0.564) 0.50 (0.779)
EQ-5D-5L 6.13 ±0.84 5.63 ±0.74 5.50 ±0.76 −0.50±0.93 −1.41 (0.157) −0.63±0.74 −1.89 (0.059) 5.20 (0.074)
  1. aWilcoxon signed-rank test; brepeated-measures ANOVA (Friedman test)